Group 1: Company Performance - Pfizer's stock is down by 5%, while Merck is holding up better [1] - Merck's guidance raised concerns due to loss of exclusivity (LOE) issues, but investors are more optimistic about its pipeline following numerous business development (BD) deals [2][3] - Pfizer's fourth quarter performance was solid with no change to guidance, but competitive metadata in phase two development of their GLP-1 drug indicates potential [3] Group 2: Investment Outlook - A neutral rating is given for both Pfizer and Merck, with a preference for Merck due to its aggressive business development efforts, despite ongoing patent cliff concerns [3][4] - The focus is on growth-oriented stocks in the sector, with Eli Lilly, Gilead, and Vertex being favored for their clean growth stories [5][6] - Future stock performance will depend on capital deployment strategies such as business development, dividend hikes, and buybacks [7]

Hello. It's great to see all of you. You know, once a year I get the benefit of thanking all of you for the incredible work that you do.As you know, we pioneered a new way of doing computing called accelerated computing. And we've been working on this for now 33 years. The big idea, the big idea is that if you could co-design, meaning if you understood the problems you're trying to compute for, and you developed the entire stack, meaning the algorithms, the computers, and the processors within it that if yo ...

Group 1: Acquisition and Market Strategy - Fizer is acquiring weight loss drug startup Metsera for $10 billion, following competition with Novo Nordisk [1] - The acquisition is part of Fizer's strategy to enter the obesity market globally, including Europe, China, the US, and Japan [6] - Fizer aims to develop a comprehensive portfolio in obesity treatment, which includes advanced GLP-1 products and innovative long-acting injections [6][7] Group 2: Product Development and Innovation - Metsera's portfolio includes a weekly GLP-1 product and a highly differentiated monthly GLP-1 product, along with a new mode of action against obesity [6][7] - Fizer plans to invest significantly in the development of these products, with a comprehensive plan targeting obesity and related comorbidities [10] - The company is optimistic about launching these products by 2028, positioning itself as a leader in the obesity treatment market [8] Group 3: Drug Pricing and Government Collaboration - Fizer has partnered with the federal government to implement most favored nation pricing for Medicaid, aiming to reduce drug costs for Americans [1][12] - The company acknowledges the high costs of drug development and the unique pricing challenges faced by consumers in the US [14] - Fizer is committed to addressing drug pricing discrepancies and has fulfilled requests from the government to improve pricing strategies [13] Group 4: Manufacturing and Investment in the US - Fizer has no dependency on China for drug components and has a robust manufacturing network in the US, with plans to invest $70 billion over the next few years [22] - The company will build manufacturing capacity for Metsera's products in the US to ensure local production for American patients [22] Group 5: Future of Medicine and AI Integration - Fizer sees a profound impact of AI on the future of medicine, particularly in drug discovery and development [23] - The company is actively integrating AI into its operations to enhance efficiency and innovation in drug development processes [24][25] - AI is expected to play a crucial role in identifying drug targets and designing effective medicines [26][27]

Risk vs Uncertainty - The insurance industry distinguishes between risk, where outcomes and probabilities are known, and uncertainty, where they are not [1] Pharmaceutical Industry Impact - The GLP1 obesity drug market is projected to reach over $471 billion by 2032, raising questions about its impact on life expectancy and potential insurance payouts [2][3] Climate Change Implications - UK property insurance payouts have reached a 20-year high, and global natural disaster costs have trebled to over $100 billion annually for the insurance industry [4] - Climate change poses a systemic threat to the financial system, potentially leading to soaring insurance costs and insurer withdrawal from climate-linked risks [5] Industry Adaptation - The insurance industry needs to shift from reactive underwriting to proactive risk mitigation in response to systemic changes [6] - Deep system changes present an opportunity for long-term investors to create a net-zero, nature-positive, socially constructive, and digitally enabled economy [6]

Endorsement & Spokespersonship - Serena Williams is a paid spokesperson for Row, a telehealth company selling weight loss drugs [2] - Williams is using GLP1 medication for weight loss and advocating for open discussion about it [2][3] - Williams' husband, Alexis O'hane, is an investor and on the board of Row [2] Weight Management & Health - Williams tried various methods like running, walking, and biking to combat weight gain before resorting to GLP1 medication [1] - Weight has been a long-standing issue for Williams, as highlighted in a 2018 documentary [2] Pharmaceutical & Telehealth Industry - Row is a telehealth company that sells weight loss drugs directly to consumers [2] - GLP1 medications are gaining popularity, with many people using them but not openly discussing it [1][3]

Market Performance & Indices - NASDAQ 100 and the composite indices reached record highs [2] - S&P 500 missed a new record by 18 or 28 cents [2] - The Dow increased by 1 and a third percent for the week [2] - NASDAQ was up almost 4% [3] Sector & Stock Movements - Tech sector led gains, up almost 1%, followed by financials and healthcare [3] - Utilities and real estate sectors posted losses for the day due to interest rate sensitivity [3] - Apple increased by 4 and a quarter percent, Alphabet up 2 and a half percent, and Tesla up over 2% [4] - UnitedHealth was up 2 and a half percent, while McDonald's slid about three-quarters of a percent, and IBM was down about 1 and a half percent [5] - Uber decreased by 3%, while FedEx and United Airlines both increased by about 1 and a half percent [6] - Micron increased by about 6%, while Microchip decreased by 6 and a half percent, and Super Micro decreased by about 4% [6] Economic Factors & Tariffs - Tariffs are expected to slow things down, with about two-thirds of the Liberation Day tariffs going into effect [10] - Inflation remaining stubbornly above 3% on CPI, coupled with a weakening consumer and labor market, could lead to a 10% to 20% correction [15] - Effective tariff rates are expected to increase by another 8% based on announced deals [23] Pharmaceutical Sector - Eli Lilly's stock decreased after the Orphaglyron attain one study showed 11-12% weight loss at 72 weeks, lower than the expected 14% [50] - Eli Lilly raised its full-year guidance, driven by Mangaro and Zetbound performance in the US and XUS [52] - Gilead is innovating in the convenience space with a twice-yearly injection for HIV prevention [60]